Fang Wang1, Qiuying Tang1, Guoxiao Lv2, Feng Zhao1, Xue Jiang1, Xinli Zhu1, Xinke Li1, Senxiang Yan3. 1. Department of Radiotherapy, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 2. Department of Radiotherapy, Dongyang People's Hospital, Jinhua, China. 3. Department of Radiotherapy, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: yansenxiang2000@163.com.
Abstract
PURPOSE: The aim of this overview was to assess the accuracy of computed tomography (CT)-based imaging technology and to compare it with magnetic resonance imaging (MRI) for the treatment planning of high-dose rate brachytherapy in cervical cancer. METHODS AND MATERIALS: A systematic search in PubMed, Embase, and the Cochrane Central was performed to identify clinical studies involving brachytherapy of cervical cancer and published before February 1, 2016. Outcomes of interest were geometric dimensions, dose parameters, and clinical results. RESULTS: After screening 675 articles, 13 clinical studies involving 465 patients were included for critical appraisal; 10 studies compared CT with MRI and three compared hybrid (CT/MRI based) with MRI only-based imaging technologies. The geometric dimensions of the high-risk clinical target volume (HR-CTV), dose parameters, and clinical outcomes were reported in 11, 10, and 1 studies, respectively. CONCLUSIONS: Among those geometric parameters of HR-CTV, width was significantly overestimated on CT compared with MRI. Height might be underestimated, and thickness was comparable. The dose parameters for HR-CTV were lower on CT only-based technique compared with MRI-based one. It is proposed that at least one pre- or at brachytherapy MRI is required to assess the tumor extension. With the help of MRI information, CT contouring will be much more accurate in cervical cancer brachytherapy.
PURPOSE: The aim of this overview was to assess the accuracy of computed tomography (CT)-based imaging technology and to compare it with magnetic resonance imaging (MRI) for the treatment planning of high-dose rate brachytherapy in cervical cancer. METHODS AND MATERIALS: A systematic search in PubMed, Embase, and the Cochrane Central was performed to identify clinical studies involving brachytherapy of cervical cancer and published before February 1, 2016. Outcomes of interest were geometric dimensions, dose parameters, and clinical results. RESULTS: After screening 675 articles, 13 clinical studies involving 465 patients were included for critical appraisal; 10 studies compared CT with MRI and three compared hybrid (CT/MRI based) with MRI only-based imaging technologies. The geometric dimensions of the high-risk clinical target volume (HR-CTV), dose parameters, and clinical outcomes were reported in 11, 10, and 1 studies, respectively. CONCLUSIONS: Among those geometric parameters of HR-CTV, width was significantly overestimated on CT compared with MRI. Height might be underestimated, and thickness was comparable. The dose parameters for HR-CTV were lower on CT only-based technique compared with MRI-based one. It is proposed that at least one pre- or at brachytherapy MRI is required to assess the tumor extension. With the help of MRI information, CT contouring will be much more accurate in cervical cancer brachytherapy.
Authors: José Richart; Vicente Carmona-Meseguer; Teresa García-Martínez; Antonio Herreros; Antonio Otal; Santiago Pellejero; Ana Tornero-López; José Pérez-Calatayud Journal: Rep Pract Oncol Radiother Date: 2018-07-23
Authors: Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan Journal: Pract Radiat Oncol Date: 2020-05-18